Observational Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2025; 17(6): 103217
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.103217
MANPOWER study: Real-world post-hoc analysis assessing essential phospholipids for non-alcoholic fatty liver disease from the Russian registry
Asad Izziddin Dajani, Branko Popovic, Caroline Amand, Sabine Tong, Kirill Maximovich Starostin, Victor Goncharuk
Asad Izziddin Dajani, ADSC, Saudi German Hospital, Sharjah, PO Box 6328, United Arab Emirates
Branko Popovic, Global Medical Affairs, A. Nattermann & Cie. GmbH, Frankfurt am Main 60315, Germany
Caroline Amand, Sabine Tong, Global Medical & PV, Opella Healthcare Group SAS, Paris 92200, France
Kirill Maximovich Starostin, General Medicines Medical, Sanofi, Moscow 125009, Russia
Victor Goncharuk, Global Regulatory Affairs, Opella Healthcare Poland sp. z o.o., Warsaw 01-211, Poland
Author contributions: Dajani AI reviewed the study design, analyzed and interpreted the data, and drafted and reviewed the manuscript; Amand C conceived and designed the study, participated in data acquisition, analyzed and interpreted the data, and drafted and reviewed the manuscript; Popovic B conceived and designed the study, interpreted the data, and drafted and reviewed the manuscript; Starostin KM conceived and designed the study, participated in data acquisition, interpreted the data, and contributed to and reviewed the manuscript; Goncharuk V conceived and designed the study, interpreted the data, contributed to and reviewed the manuscript; Tong S analyzed the data, and drafted and reviewed the manuscript. All authors approved the final version of the manuscript to be published.
Institutional review board statement: The study was approved by the Independent Interdisciplinary Ethics Committee on Ethical Review for Clinical Studies, which is the operating ethics committee in the Russian Federation (Protocol #13 dated 28 August 2015).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: Dajani AI has no conflict of interest. Popovic B, Amand C, Starostin KM, Tong S and Goncharuk V are employees of Sanofi and may hold shares or stock options in the company.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The data that support the findings of this study are not publicly available but are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Branko Popovic, MD, Global Medical Affairs, A. Nattermann & Cie. GmbH, Aqua Tower, Junghofstraße 9, Frankfurt am Main 60315, Germany. branko.popovic@sanofi.com
Received: November 13, 2024
Revised: March 10, 2025
Accepted: May 21, 2025
Published online: June 27, 2025
Processing time: 225 Days and 17.2 Hours
Core Tip

Core Tip: Essentiale Forte N®, administered as adjunctive therapy in patients with non-alcoholic fatty liver disease (NAFLD), reduced liver enzyme levels [alanine transaminase (ALT), aspartate transaminase (AST) and gamma-glutamyl transferase (GGT)] and improved ultrasonographic features of NAFLD, particularly with regard to liver hyperechogenicity and structure, with a greater reduction noted with increasing NAFLD severity. These data indicate that Essentiale, alone or in combination with other treatment, is effective for the management of NAFLD. Additionally, a non-invasive diagnostic algorithm based on the statistical distribution of three liver enzymes (ALT, AST, and GGT) could be used to increase the accuracy of diagnosis, staging, and monitoring of patients with NAFLD.